Nancy Lurker - 09 Feb 2022 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
President & CEO, Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
09 Feb 2022
Net transactions value
$0
Form type
4
Filing time
11 Feb 2022, 15:38:12 UTC
Previous filing
17 Nov 2021
Next filing
23 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +17,533 +16% $0.000000 124,098 09 Feb 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -17,533 -33% $0.000000 35,067 09 Feb 2022 Common Stock 17,533 $0.000000 Direct F2
transaction EYPT Restricted Stock Units Award $0 +60,000 $0.000000 60,000 09 Feb 2022 Common Stock 60,000 $0.000000 Direct F3
transaction EYPT Stock Option (Right to Buy) Award $0 +240,000 $0.000000 240,000 09 Feb 2022 Common Stock 240,000 $10.13 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 3,019 shares acquired on January 31, 2022 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2 The restricted stock units vest in three ratable annual installments beginning February 9, 2022.
F3 These restricted stock units will vest in three ratable annual installments beginning February 9, 2023.
F4 The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.